Nivolumab with cisplatin and radiotherapy improved 3-year disease-free survival to 63.1% versus 52.5% in high-risk head and neck cancer patients. The trial enrolled 680 patients, with Opdivo ...

The proportion of patients achieving a complete response (CR) with enfortumab vedotin (EV) plus pembrolizumab (P; Keytruda) was double that of those who received platinum-based chemotherapy, and CRs ...

RAHWAY, NJ, USA I May 30, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study ...

Zilovertamab vedotin is an investigational, potential first-in-class antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). At a pre-planned analysis ...

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory ...

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation ...

Nemes Laszlo via Shutterstock. Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), has demonstrated promise in a Phase ...

Published literature demonstrates that these cancers express the protein, nectin-4. Nectin-4 serves as an important target for the anticancer medication enfortumab vedotin (EV), which has been shown ...